Fredun Pharmaceuticals launched 'DAULCÉL', a premium wellness and longevity-focused brand centered on NAD+ science and preventive healthcare.
The strategic expansion targets growing demand for cellular vitality, healthy aging, and lifestyle-oriented wellness solutions globally.
The initiative leverages Fredun's pharmaceutical expertise to diversify into high-growth wellness categories and strengthen its specialty healthcare portfolio.
FY25 financials show revenues of ₹456 Cr, EBITDA of ₹55 Cr, and PAT of ₹21 Cr, providing context for the expansion.